Gilpin Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
Other funds holding CPRX
Gilpin Wealth Management's CPRX Position: Q3 2026 in Review
Gilpin Wealth Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 23 shares — an estimated $723 sold.
Gilpin Wealth Management first reported a position in CPRX in Q4 2025 and held it in 3 quarters. The position peaked at $723 in Q2 2026. 2 funds tracked by Wall St. Rank hold CPRX as of Q3 2026.
- Gilpin Wealth Management reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
- Gilpin Wealth Management sold 23 Catalyst Pharmaceutical shares in Q3 2026, an estimated $723.
- Gilpin Wealth Management first reported a position in Catalyst Pharmaceutical in Q4 2025 and held it in 3 quarters.
- Gilpin Wealth Management's Catalyst Pharmaceutical position peaked at $723 in Q2 2026.
- 2 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.
Based on Gilpin Wealth Management's 13F filing for Q3 2026, filed 9 Oct 2026.